1. In Vivo

MedTech Forum 2019: Building Growth In The Outcomes Era

Value-Based Outcomes Mean Medtech CEOs Must Look Within As Well As Upwards

 
• By Ashley Yeo

The European MedTech Forum’s CEO panel set out to address high-level global, long-range issues, but from the start it got log jammed in regulatory issues. Not in the script perhaps, but wholly understandable, as new EU regulations will have huge strategic importance for how companies do business – and in the case of start-ups, if they can continue to do business.

CEOs_panel_MTF_2019
CEO panelists at MedTech Forum 2019 • Source: Ashley Yeo

Had there been a table in front of him, ResMed CEO Mick Farrell would have lent forward and banged it hard with his fist. Twenty minutes into a one-hour session at the 2019 MedTech Forum on burning issues for global medtech CEOs, and we were talking – still – about the current and potential effects on business and patient care of the EU Medical Device Regulation; “we” being the Peters Surgical (Bobigny, France) and Werfen (Barcelona, Spain) CEOs Thierry Herbreteau and Carlos Pascual, along with Farrell.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Eleanor Malone

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By Ashley Yeo

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.

Financing Quarterly Statistics, Q1 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.